Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Some patients need slower titration
It additionally reduces food intake by lowering appetite and slows down digestion in the stomach
While pre-clinical data has been encouraging, clinical evidence remains limited
Medicaid Coverage by State Medicaid coverage for weight loss medication varies dramatically by state, and this variability is one of the most significant equity issues in obesity medicine
What the Clinical Evidence Shows While large-scale randomized controlled trials specifically measuring testosterone as a primary endpoint in tirzepatide users are still emerging, the available evidence is encouraging: The SURMOUNT trials demonstrated average weight losses of 15-22.5% of body weight, a degree of fat reduction strongly associated with testosterone recovery in men with obesity-related hypogonadism (Jastreboff et al., 2022, NEJM )
US$ 20.57
)
US$ 24.15
US$ 23.33
)
)
US$ 25.55
